Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 22, 2013 - Issue 11
Submit an article Journal homepage
602
Views
18
CrossRef citations to date
0
Altmetric
Reviews

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia

Paul LeeUniversity of Western Ontario, Schulich School of Medicine and Dentistry, Department of Medicine and Robarts Research Institute, London, Ontario, N6A 5K8, Canada
&
Robert A HegeleWestern University, Department of Medicine, Schulich School of Medicine and Dentistry, London, Ontario, Canada+519 931 5271; +519 931 5218; [email protected]
, MD FRCPC FACP
Pages 1411-1423 | Published online: 26 Jul 2013

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Steven E Gryn & Robert A Hegele. (2015) Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy 16:8, pages 1255-1262.
Read now
Shobha Ghosh, Jinghua Bie, Jing Wang, Quan Yuan & Siddhartha S Ghosh. (2014) Cholesterol removal from plaques and elimination from the body: change in paradigm to reduce risk for heart disease. Clinical Lipidology 9:4, pages 429-440.
Read now

Articles from other publishers (16)

Haley Yost, Riya Patel, Anders Kipp & Tanea T. Reed. 2005. Bailey's Industrial Oil and Fat Products. Bailey's Industrial Oil and Fat Products 1 29 .
Jie Bai, Li-lin Gong, Qi-fu Li & Zhi-hong Wang. (2018) Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials. Journal of Clinical Lipidology 12:2, pages 277-291.e3.
Crossref
Linda R. Wang & Robert A. Hegele. (2017) Genetics for the Identification of Lipid Targets Beyond PCSK9. Canadian Journal of Cardiology 33:3, pages 334-342.
Crossref
Jiao Li, Xue Liang, Yuanyuan Wang, Zhao Xu & Guangping Li. (2017) Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis. Molecular Medicine Reports 16:2, pages 1817-1825.
Crossref
Hermann Toplak, Bernhard Ludvik, Monika Lechleitner, Hans Dieplinger, Bernhard Föger, Bernhard Paulweber, Thomas Weber, Bruno Watschinger, Sabine Horn, Thomas C. Wascher, Heinz Drexel, Marianne Brodmann, Ernst Pilger, Alexander Rosenkranz, Erich Pohanka, Rainer Oberbauer, Otto Traindl, Franz Xaver Roithinger, Bernhard Metzler, Hans-Peter Haring & Stefan Kiechl. (2016) Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complicationsÖsterreichischer Lipidkonsensus. Management von Fettstoffwechselstörungen zur Prävention vaskulärer Komplikationen. Wiener klinische Wochenschrift 128:S2, pages 216-228.
Crossref
J. David Spence & George K. Dresser. (2016) Overcoming Challenges With Statin Therapy. Journal of the American Heart Association 5:1.
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs 285 315 .
Steven E. Gryn & Robert A. Hegele. (2015) Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology 26:6, pages 484-491.
Crossref
Erica Hoe & Robert A. Hegele. (2015) Lipid Management in Diabetes with a Focus on Emerging Therapies. Canadian Journal of Diabetes 39, pages S183-S190.
Crossref
Ruth McPhersonRobert A. Hegele. (2015) Ezetimibe. Arteriosclerosis, Thrombosis, and Vascular Biology 35:3.
Crossref
Yan Zhang, Cheng-Gang Zhu, Rui-Xia Xu, Sha Li, Yuan-Lin Guo, Jing Sun & Jian-Jun Li. (2014) Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. Journal of Clinical Lipidology 8:5, pages 494-500.
Crossref
Anette Varbo & Børge G. Nordestgaard. (2014) Remnant cholesterol and ischemic heart disease. Current Opinion in Lipidology 25:4, pages 266-273.
Crossref
Ursula Kassner, Marion Wühle-Demuth, Isabelle Missala, Steve E Humphries, Elisabeth Steinhagen-Thiessen & Ilja Demuth. (2013) Clinical utility gene card for: Hyperlipoproteinemia, TYPE II. European Journal of Human Genetics 22:7, pages 953-953.
Crossref
S E Gryn & R A Hegele. (2014) Pharmacogenomics, Lipid Disorders, and Treatment Options. Clinical Pharmacology & Therapeutics 96:1, pages 36-47.
Crossref
Anette Varbo, Marianne Benn & Børge G. Nordestgaard. (2014) Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacology & Therapeutics 141:3, pages 358-367.
Crossref
My-Anh Nguyen, Tanja Kosenko & Thomas A. Lagace. (2014) Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. Journal of Lipid Research 55:2, pages 266-275.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.